A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

NCT03537651 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: TEZ/IVA
DRUG: IVA

Sponsor

Vertex Pharmaceuticals Incorporated